MedTrace Logo

Montalcino Aortic Consortium: Precision Medicine for Heritable Thoracic Aortic Disease

NCT04005976 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2026-02-02

No results posted yet for this study

Summary

The Montalcino Aortic Consortium (MAC) will provide the infrastructure to assemble large cohorts of patients with mutations in known heritable thoracic aortic disease (H-TAD) genes, define the phenotype associated with these genes, and determine genetic and environmental modifiers of H-TAD.

Conditions

  • Aortic Aneurysm
  • Aortic Dissection
  • Aortic Diseases

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Dianna Milewicz, MD, PhD · UTHealth

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-15
Primary Completion
2037-01-01
Completion
2037-01-01

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04005976 on ClinicalTrials.gov